NCT04587271

Brief Summary

Studies to date on the effects of Moringa oleifera in diabetes and anemia and animal studies that examine the utility of moringa for increased milk and litter yield are of small scale, however high-quality large-scale placebo or case-controlled clinical trials to define the impact on infants of moringa leaf powder consumption by breastfeeding mothers are lacking. Moringa has a traditional and agricultural history of use as a galactagogue; despite this and its incorporation into products such as Mother's Milk Tea© and placement on NIH LactMed Lactation Database, this property has not been studied in large clinical trials nor in populations dependent on breastmilk such as in Kisumu, Kenya. This study will improve and add to existing knowledge of moringa's effect on human breastmilk and will provide novel information on the effect of moringa supplementation to lactating mothers on their infant's intestinal inflammation and health. After trial registration, the study was modified to include infant follow up to 18 months for some measures and the children's groups were removed. Although the study was modified to an 18 month follow up, the data were not able to be collected. Further understanding of the acceptability of moringa leaf in a staple food of porridge and more the effect of moringa supplementation on infant and childhood growth, nutrition, and intestinal and systemic inflammation may translate in the future to the cultivation of moringa at the community or household level as an effective resource for the improvement of childhood undernutrition.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2021

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 8, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 14, 2020

Completed
9 months until next milestone

Study Start

First participant enrolled

July 21, 2021

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 4, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 4, 2022

Completed
1.2 years until next milestone

Results Posted

Study results publicly available

November 22, 2023

Completed
Last Updated

November 22, 2023

Status Verified

October 1, 2023

Enrollment Period

1.1 years

First QC Date

October 8, 2020

Results QC Date

July 24, 2023

Last Update Submit

October 31, 2023

Conditions

Keywords

Moringa oleiferasupplementation

Outcome Measures

Primary Outcomes (1)

  • Change in Body Weight

    Body weight

    at baseline and 3 months

Secondary Outcomes (11)

  • Change in Infant Height

    at baseline and 3 months

  • Change in Mid-Upper Arm Circumference

    baseline and 3 months

  • Change in Vitamin A

    3 months

  • Change in CRP Levels

    baseline and 3 months

  • Change in the Soluble Transferrin Receptor

    baseline and 3 months

  • +6 more secondary outcomes

Study Arms (6)

Lactating Mothers (Moringa)

EXPERIMENTAL

Lactating mothers.

Dietary Supplement: Moringa oleifera (high dose)

Breastfeeding Infants (Moringa)

EXPERIMENTAL

Breastfeeding infants from lactating mothers

Dietary Supplement: Moringa oleifera (high dose)

Children (Moringa)

EXPERIMENTAL

Children from 6-59 months of age.

Dietary Supplement: Moringa oleifera (low dose)

Lactating Mothers (placebo)

PLACEBO COMPARATOR

Lactating mothers.

Dietary Supplement: Placebo

Breastfeeding Infants (placebo)

PLACEBO COMPARATOR

Breastfeeding infants from lactating mothers

Dietary Supplement: Placebo

Children (placebo)

PLACEBO COMPARATOR

Children from 6-59 months of age.

Dietary Supplement: Placebo

Interventions

Mothers will receive 20 grams of moringa leaf powder in porridge consumed daily for three months.

Breastfeeding Infants (Moringa)Lactating Mothers (Moringa)
Moringa oleifera (low dose)DIETARY_SUPPLEMENT

Children will receive 5-10 grams of moringa leaf powder in porridge consumed daily for three months.

Children (Moringa)
PlaceboDIETARY_SUPPLEMENT

Mothers and children will receive porridge with placebo.

Breastfeeding Infants (placebo)Children (placebo)Lactating Mothers (placebo)

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • lactating women at least 18 years of age and their exclusively breastfed infants within 14 days of delivery.
  • children 6-59 months of age who eat food

You may not qualify if:

  • regular maternal consumption of moringa
  • receipt and consumption of food supplementation program
  • inability to feed orally or refusal to eat moringa or placebo porridge
  • for infants, prematurity (\<36 weeks gestational age)
  • for infants, significant congenital disease
  • for infants, inability to feed orally

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Kombewa County Hospital

Kisumu, 40102, Kenya

Location

Chulaimbo Sub- County Hospital

Kisumu, 40105, Kenya

Location

Related Publications (1)

  • Attia SL, Owuor PM, Odhiambo SA, Mogaka JN, Ondondo R, Navarro IC, Schadler A, McQuerry K, Fuchs GJ 3rd, Williams JE, Scarrow KN, McGuire MA, McGuire MK, Waterman C. Effect of Maternal Moringa oleifera Leaf Supplementation on Maternal and Infant Nutritional Status and Human Milk Output: A Pilot Single-Blinded Cluster-Randomized Trial. Curr Dev Nutr. 2025 Oct 3;9(11):107568. doi: 10.1016/j.cdnut.2025.107568. eCollection 2025 Nov.

MeSH Terms

Conditions

MalnutritionCachexiaFailure to Thrive

Condition Hierarchy (Ancestors)

Nutrition DisordersNutritional and Metabolic DiseasesWeight LossBody Weight ChangesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsThinness

Results Point of Contact

Title
Dr. Suzanna Attia
Organization
University of Kentucky

Study Officials

  • Suzanna L Attia

    University of Kentucky

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

October 8, 2020

First Posted

October 14, 2020

Study Start

July 21, 2021

Primary Completion

September 4, 2022

Study Completion

September 4, 2022

Last Updated

November 22, 2023

Results First Posted

November 22, 2023

Record last verified: 2023-10

Data Sharing

IPD Sharing
Will not share

Locations